Begins a senior secured debt issuance process to refinance senior unsecured debt maturing in 2025

MADRID, 10 Abr. (EUROPA PRESS) –

Grifols will allocate the proceeds from the sale of 20% of its stake in Shanghai RAAS Blood to Haier, through its subsidiary Qingdao Medical Haier Medical Technology, to reduce secured debt, as detailed this Wednesday by the company to the National Securities Market Commission (CNMV).

In this sense, the blood products firm has recalled that it continues to make progress in closing the transaction, which it expects to conclude in the first half of 2024, as planned.

In addition, the company has explained that it has initiated a senior secured debt issuance process to refinance senior unsecured debt maturing in 2025, a process on which it is “actively” working.

If the transaction is carried out successfully, the blood products company has indicated that it will proceed “to make the pertinent communications to keep the market informed.”

In this way, Grifols has confirmed its commitment “to meet debt maturities in 2025”, while clarifying the destination of Shanghai RAAS funds, as company sources have indicated to Europa Press.

Last week, Grifols sent the CNMV the information required by the supervisory body in which it revealed that it will proceed to reduce to two the number of measures used to reflect the gross operating result (Ebitda) in its results communications, and placed the debt net in 2023 at 10,527 million euros, with 1,111 million in leasing contracts.